Rockville, Maryland (US), August 23, 2024 Advanced BioScience Laboratories, Inc. (ABL), a Contract Development and Manufacturing Organization (CDMO) to the U.S. Government and biopharmaceutical industry, announced that it has been awarded two (2) new Indefinite Delivery, Indefinite Quantity (IDIQ) contracts for “Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances and Drug Products” by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) of the U.S. Department of Health and Human Services (HHS), contract numbers 75N95024D00008 and 75N95024D00013.

ABL, as one of the awardees of these IDIQ contract pools, will provide NCATS with process and analytical development as well as current Good Manufacturing Practice (cGMP) essential manufacturing services to support translational development of therapeutic biotechnology (biologics) products of various modalities for their drug discovery and development programs. ABL is proud to support NCATS to conduct innovative, translational research on human therapeutics development by accelerating critical biologic drug candidates in the drug development pipeline to IND submission. ABL is honored to continue its strategic collaboration with NCATS and other government agencies in support of their mission.

“Award of these two complementary IDIQ contracts is a testament to ABL’s dedication and expertise in advancing therapeutic biologics on behalf of our clients. We are honored to support NCATS in their mission to accelerate the development of life-saving drug candidates by means of translational development. This award underscores our commitment to excellence in analytical development, process development, GMP manufacturing of drug substances and fill finish of drug products, allowing the ABL team the inspiring opportunity to contribute to the future of drug discovery and development,” said Lauren Hudacik, President and CEO of ABL.

About ABL

ABL is a contract development and manufacturing organization dedicated to advancing therapeutics, vaccines and other biological products. ABL has extensive experience working with diverse organizations including industry, government and academic entities. ABL maintains GMP facilities meeting U.S. regulatory standards, providing manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines. Our services include bulk drug substance, live virus fill/finish, process and assay development.

Advanced BioScience Laboratories, Inc

9800 Medical Center Drive, Building D

Rockville, MD 20850

www.ablinc.com

Contact: Christina Mayer

Phone: 301-816-5295

Email: christina.mayer@ablinc.com